Invivo Therapeutics Holdings Corp. (NVIV) 10-Q Quarterly Report August 2019

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 05, 2019
Document and Entity Information
Entity Registrant Name	InVivo Therapeutics Holdings Corp.
Entity Central Index Key	0001292519
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,311,820
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1292519/000155837019008016/nviv-20190630x10q.htm

View differences made from one quarter to another to evaluate Invivo Therapeutics Holdings Corp.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Invivo Therapeutics Holdings Corp..

Continue

Assess how Invivo Therapeutics Holdings Corp.'s management team is paid from their Annual Proxy

Invivo Therapeutics Holdings Corp.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Revenue

Financial

Other

Filter Subcategory:

All

Product

Expense

Other

Inside Invivo Therapeutics Holdings Corp.'s 10-Q Quarterly Report:

Revenue - Product Highlight
On May 30, 2018, our stockholders approved to increase the issuance and sale by us to Lincoln Park, including our prior issuances and sales of shares of Common Stock to Lincoln Park since January 2018, of up to 1,200,000 shares of Common Stock.

Financial - Expense Highlight
This estimate is based on assumptions that may prove to be wrong; expenses could prove to be significantly higher, leading to a more rapid consumption of our existing resources.
Financial - Expense Highlight
The increase in research and development expenses for the three months ended June 30, 2019 is attributable to an increase clinical trial and scaffold manufacturing costs of $562 thousand and $97 thousand respectively, related to the opening up of new clinical trial sites in 2019 and an increase in facilities and rent expense of $269 thousand.
Financial - Expense Highlight
These costs were offset by increases in facilities and rent expense of $218 thousand.
Financial - Expense Highlight
General and administrative expenses for the three months ended June 30, 2019 were $1.5 million, a decrease of $254 thousand compared to the three months ended June 30, 2018.
Financial - Expense
26 General and administrative expenses...Read more
Financial - Expense
The change in net cash...Read more
Other - Other
In 1 example, if 50%...Read more
Other - Other
In another example, if 40%...Read more
Financial - Expense
The increase in research and...Read more
Other - Other
Of these 16, 7 had...Read more
Financial - Shares
During the three and six...Read more
Other - Other
3 of the 7 patients...Read more
Other - Other
2 of the 16 patients...Read more
Financial - Expense
The decrease in general and...Read more
Financial - Expense
Research and development expenses for...Read more
Financial - Expense
Research and development expenses for...Read more
Financial - Expense
We may alternatively engage in...Read more
Other - Other
1 of these 2 was...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Invivo Therapeutics Holdings Corp. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: NVIV
CIK: 1292519
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-19-008016
Submitted to the SEC: Tue Aug 13 2019 4:01:16 AM EST
Accepted by the SEC: Tue Aug 13 2019
Period: Sunday, June 30, 2019
Industry: Surgical And Medical Instruments And Apparatus